Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.94 |
| ▸ | HTR1A | P08908 | 3/20 | 0.94 |
| ▸ | HTR2A | P28223 | 2/20 | 0.94 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.94 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.94 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.94 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.94 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.94 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.94 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.94 |
| ▸ | HTR2C | P28335 | 1/20 | 0.94 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.94 |
| ▸ | HRH1 | P35367 | 1/20 | 0.94 |
| ▸ | HTR2B | P41595 | 1/20 | 0.94 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.94 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.94 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.94 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxypertine SCHEMBL1515 | 0.97 | DRD2 (1.00) | DRD2HTR1AHTR2ANR1I2ADRB1 | |
| Oxypertine SCHEMBL2463001 | 0.97 | DRD2 (1.00) | DRD2HTR1AHTR2ANR1I2ADRB1 | |
| Oxypertine SCHEMBL31153315 | 0.97 | DRD2 (1.00) | DRD2HTR1AHTR2ANR1I2ADRB1 | |
| Oxypertine SCHEMBL5069690 | 0.96 | DRD2 (0.98) | DRD2HTR1AHTR2ANR1I2ADRB1 | |
| Oxypertine SCHEMBL3478579 | 0.96 | DRD2 (0.98) | DRD2HTR1AHTR2ANR1I2ADRB1 | |
| Oxypertine SCHEMBL20270862 | 0.96 | DRD2 (0.98) | DRD2HTR1AHTR2ANR1I2ADRB1 | |
| Oxypertine SCHEMBL3440995 | 0.96 | DRD2 (0.98) | DRD2HTR1AHTR2ANR1I2ADRB1 | |
| Oxypertine SCHEMBL21268763 | 0.94 | HTR1A (0.94) | DRD2HTR1AHTR2ANR1I2ADRB1 | |
| Oxypertine SCHEMBL7527152 | 0.91 | HTR1A (0.88) | DRD2HTR1AHTR2ANR1I2ADRB1 | |
| SCHEMBL2615395 | 0.89 | DRD2 (0.84) | DRD2HTR1AHTR2ANR1I2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2730282-A1 | Methods and compositions for the treatment of proteinuric diseases | The General Hospital Corporation (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| EP-2217238-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | The General Hospital Corporation (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061448-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009061448-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20080064716-A1 | Alpha v beta 3 and/or alpha v beta 5 integrin inhibitors; osteoporosis, retinopathy, tumor metastasis and angiogenesis; decreased side effects, improved potency; 3-(2-(3-[2-(5,6,7,8- Tetrahydro-1,8-naphthyridin-2-yl)ethoxy]benzyl}-phenyl)propionic acid | PHARMACIA | 2008-03-13 | — | — | US | disclosed |
| US-20080064716-A1 | Alpha v beta 3 and/or alpha v beta 5 integrin inhibitors; osteoporosis, retinopathy, tumor metastasis and angiogenesis; decreased side effects, improved potency; 3-(2-(3-[2-(5,6,7,8- Tetrahydro-1,8-naphthyridin-2-yl)ethoxy]benzyl}-phenyl)propionic acid | PHARMACIA | 2008-03-13 | — | — | US | disclosed |
| EP-1802618-A1 | BIPHENYL INTEGRIN ANTAGONISTS | Pharmacia Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1802618-A1 | BIPHENYL INTEGRIN ANTAGONISTS | Pharmacia Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006043930-A1 | BIPHENYL INTEGRIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006043930-A1 | BIPHENYL INTEGRIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | DRD2 4797/4885HTR1A 4517/4885HTR2A 4073/4885 |
| US-20080064716-A1 | Alpha v beta 3 and/or alpha v beta 5 integrin inhibitors; osteoporosis, retinopathy, tumor metastasis and angiogenesis; decreased side effects, improved potency; 3-(2-(3-[2-(5,6,7,8- Tetrahydro-1,8-naphthyridin-2-yl)ethoxy]benzyl}-phenyl)propionic acid | ITGA5, ITGAV, ITGB5 | DRD2 2127/4885HTR1A 2510/4885HTR2A 3876/4885 |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | DRD2 4797/4885HTR1A 4517/4885HTR2A 4073/4885 |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | ITGB3, PLAUR, PROC | DRD2 4797/4885HTR1A 4517/4885HTR2A 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.